Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver entities : Albireo pharma, inc. save search
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
Published: 2023-01-09 (Crawled : 11:00) - biospace.com/
ALBO | $44.15 -0.23% 0.39% 1.2M
|
Health Technology
|
| O: 91.65%
H: 0.0%
C: 0.0%
rare liver acquire disease growth
Albireo to Showcase New Data at AASLD The Liver Meeting® 2022
Published: 2022-10-05 (Crawled : 17:00) - biospace.com/
ALBO | $44.15 -0.23% 0.39% 1.2M
|
Health Technology
|
| O: 2.35%
H: 4.74%
C: 4.48%
meeting liver
Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases
Published: 2022-06-23 (Crawled : 14:00) - biospace.com/
ALBO | $44.15 -0.23% 0.39% 1.2M
|
Health Technology
|
| O: 0.1%
H: 0.0%
C: 0.0%
liver presentation disease
Albireo Presented Data in Cholestatic Liver Diseases at Digestive Disease Week (DDW) 2022
Published: 2022-05-23 (Crawled : 14:00) - biospace.com/
ALBO | $44.15 -0.23% 0.39% 1.2M
|
Health Technology
|
| O: 1.3%
H: 0.4%
C: -4.64%
liver disease week
Albireo Announces Publication of the PICTURE Study Highlighting the Caregiver Impact of PFIC, a Rare and Devastating Children’s Liver Disease
Published: 2022-02-14 (Crawled : 14:30) - biospace.com/
ALBO | $44.15 -0.23% 0.39% 1.2M
|
Health Technology
|
| O: 0.0%
H: 1.24%
C: -1.58%
rare liver disease liver disease children
Albireo Announces New Phase 3 Data for Bylvay™ (odevixibat) in PFIC and First Reveal of New Next Generation Bile Acid Modulator Data at AASLD The Liver Meeting® 2021
Published: 2021-11-12 (Crawled : 14:00) - albireopharma.com
ALBO | $44.15 -0.23% 0.39% 1.2M
|
Health Technology
|
| O: -0.98%
H: 0.0%
C: 0.0%
phase 3 liver
Albireo to Showcase New Data at AASLD The Liver Meeting® 2021
Published: 2021-10-15 (Crawled : 14:00) - biospace.com/
ALBO | $44.15 -0.23% 0.39% 1.2M
|
Health Technology
|
| O: 1.13%
H: 0.73%
C: -0.57%
liver
Albireo Announces Expanded Phase 3 Data on Bylvay™ (odevixibat) and A3907 at Upcoming EASL International Liver Congress
Published: 2021-06-21 (Crawled : 11:00) - globenewswire.com
ALBO | $44.15 -0.23% 0.39% 1.2M
|
Health Technology
|
| O: 0.82%
H: 3.42%
C: 2.32%
phase 3 liver a3907
Albireo to Showcase New Data at the EASL International Liver Congress™ 2021
Published: 2021-06-10 (Crawled : 13:00) - globenewswire.com
ALBO | $44.15 -0.23% 0.39% 1.2M
|
Health Technology
|
| O: 0.74%
H: 2.77%
C: 0.46%
liver
Albireo Recognizes International Alagille Syndrome Awareness Day 2021Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases
Published: 2021-01-22 (Crawled : 15:00) - biospace.com/
ALBO | $44.15 -0.23% 0.39% 1.2M
|
Health Technology
|
| O: -0.75%
H: 1.53%
C: 1.27%
disease education liver treatment syndros rare
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
ILAG | $0.51 6.03% 29.06% 430K
|
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.